Serotonin syndrome produced by a combination of venlafaxine and mirtazapine.
Dimellis
Dimos
D
D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D000328:Adult; D000929:Antidepressive Agents, Tricyclic / Q000627:therapeutic use*; D003511:Cyclohexanols / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D008140:Lorazepam / Q000627:therapeutic use; D008803:Mianserin / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D000078785:Mirtazapine; D011433:Propranolol / Q000627:therapeutic use; D020230:Serotonin Syndrome / Q000188:drug therapy*; D017367:Selective Serotonin Reuptake Inhibitors / Q000627:therapeutic use*; D000069470:Venlafaxine Hydrochloride
D000319:Adrenergic beta-Antagonists; D000929:Antidepressive Agents, Tricyclic; D003511:Cyclohexanols; D008140:Lorazepam; D008803:Mianserin; D000078785:Mirtazapine; D011433:Propranolol; D017367:Selective Serotonin Reuptake Inhibitors; D000069470:Venlafaxine Hydrochloride